Search research articles
Contact Us
Filters
Showing results (111-120 of 118) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 118 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 13, 2011
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer
F Rojo, J García-Parra, S Zazo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 10, 2011
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer
J Albanell, A González, M Ruiz-Borrego, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 13, 2021
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER)
J Albanell, M T Martínez, M Ramos, et al.
Journal of Mammary Gland Biology and Neoplasia
|
November 8, 2024
Gestational breast cancer: distinctive molecular and clinico-epidemiological features
J R de la Haba-Rodríguez, P Mínguez, F Rojo, et al.
Scientific Reports
|
May 18, 2019
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
A Borrero-Palacios, A Cebrián, M T Gómez Del Pulgar, et al.
Scientific Reports
|
February 24, 2019
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
A Borrero-Palacios, A Cebrián, M T Gómez Del Pulgar, et al.
BMC Cancer
|
December 3, 2022
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study
L de la Cruz-Merino, M Gion, J Cruz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
P Tarantino, G Viale, M F Press, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 118) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 118 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 13, 2011
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer
F Rojo, J García-Parra, S Zazo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 10, 2011
Prospective transGEICAM study of the impact of the 21-gene Recurrence Score assay and traditional clinicopathological factors on adjuvant clinical decision making in women with estrogen receptor-positive (ER+) node-negative breast cancer
J Albanell, A González, M Ruiz-Borrego, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 13, 2021
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER)
J Albanell, M T Martínez, M Ramos, et al.
Journal of Mammary Gland Biology and Neoplasia
|
November 8, 2024
Gestational breast cancer: distinctive molecular and clinico-epidemiological features
J R de la Haba-Rodríguez, P Mínguez, F Rojo, et al.
Scientific Reports
|
May 18, 2019
Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
A Borrero-Palacios, A Cebrián, M T Gómez Del Pulgar, et al.
Scientific Reports
|
February 24, 2019
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
A Borrero-Palacios, A Cebrián, M T Gómez Del Pulgar, et al.
BMC Cancer
|
December 3, 2022
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015-04 (PANGEA-Breast) study
L de la Cruz-Merino, M Gion, J Cruz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 3, 2023
ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
P Tarantino, G Viale, M F Press, et al.
Page
of 12